REGENXBIO Inc. RGNX

Health CareBiotechnology & Medical ResearchUnited States of America

Last close 7.63 USD on Nov 3, 2026, −47.0% year to date

Quant rating

Quant rating C Rank 357 of 565 in Health Care

Growth B 119 of 565
Valuation C 353 of 565
Quality C 243 of 565
Revisions C 356 of 565
Momentum D 485 of 565

Wall Street consensus Buy (1.75)Average target 25.42 USD +233.1%

Historical valuation

Multiples use consensus estimates for the next twelve months. The dashed line is the 5-year average.

Key data

Market cap: 504M
Enterprise value: 580M
52-week range: 5.46 – 16.19
3-year range: 5.31 – 24.61
Dividend yield: –
Beta (5 years): 1.22
Shares outstanding: 66.0M
Next earnings: Nov 5, 2026

About the company

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). It is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.

Growth and profitability

Growth and profitability by fiscal year
	2025	2024	2023	2022	2021	5Y avg
Revenue (mil)	170	83.3	90.2	113	470	–
Revenue growth	104.5%	−7.7%	−19.9%	−76.0%	204.3%	2.0%
EPS (basic, normalized)	−3.76	−4.59	−6.02	−6.50	2.91	–
EPS growth	–	–	–	–	–	–
Gross margin	88.1%	59.7%	58.8%	51.6%	89.0%	69.4%
Net margin	−113.8%	−272.5%	−292.0%	−248.7%	27.2%	−180.0%
ROE	−107.0%	−79.5%	−63.7%	−43.8%	22.4%	−54.3%

Balance sheet, last quarter
Cash & short-term investments (mil)	106
Current ratio	2.86x
Long-term debt (mil)	155
Net debt (mil)	76.0
Total equity (mil)	71.8
Net debt / equity	1.06x
Net debt / EBITDA	–

Estimates and valuation

Consensus estimates and implied multiples
	Sales (mil)			EBITDA (mil)			EPS
Fiscal year	Mean est.	Growth	EV/Sales	Mean est.	Growth	EV/EBITDA	Mean est.	Growth	P/E
2025 actual	170	+104.5%	3.4x	–	–	–	−3.76	+18.1%	−2.0x
2026	154	−9.4%	3.8x	−176	–	−3.3x	−3.48	+7.5%	−2.2x
2027	215	+39.5%	2.7x	−148	+15.6%	−3.9x	−3.06	+12.0%	−2.5x
2028	326	+51.6%	1.8x	−109	+26.3%	−5.3x	−1.99	+34.9%	−3.8x

Estimate revisions

Change in consensus estimates over 1, 3 and 6 months
	Sales				EPS
Fiscal year	Estimate (mil)	1M	3M	6M	Estimate	1M	3M	6M
2026	154	−7.2%	−29.9%	−38.9%	−3.48	−3.2%	−20.8%	−40.7%
2027	215	+2.9%	−16.4%	−28.4%	−3.06	+4.2%	−16.7%	−8.8%
2028	326	−5.2%	−6.8%	−33.5%	−1.99	−9.5%	+6.2%	−11.6%

Earnings surprises EPS beat in 2 of the last 4 quarters

Reported results versus consensus, last 10 fiscal quarters
Quarter ended	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales reported (mil)	15.6	22.3	24.2	21.2	89.0	21.4	29.7	30.3	6.4	108
Sales mean (mil)	23.5	23.0	23.6	23.8	102	28.1	24.1	36.6	26.3	117
Surprise	−33.6%	−3.0%	+2.6%	−10.7%	−12.7%	−24.0%	+23.2%	−17.0%	−75.7%	−7.8%
EPS reported	−1.33	−1.05	−1.17	−1.01	0.12	−1.38	−1.20	−1.30	−1.72	0.43
EPS mean	−1.26	−1.29	−1.12	−1.15	0.48	−1.10	−1.31	−0.96	−1.34	0.06
Surprise	−5.6%	+18.7%	−4.3%	+11.9%	−75.1%	−25.5%	+8.1%	−36.0%	−28.5%	+641.4%

Peer comparison Biotechnology & Medical Research

Peers in the same industry group, by market capitalization
Company	Market cap	Net debt/EBITDA	Net margin	P/B	FY1 P/E	FY2 P/E	FY1 EV/EBITDA	FY2 EV/EBITDA
RGNX REGENXBIO Inc.	504M	–	−113.8%	5.76x	−2.2x	−2.5x	−3.3x	−3.9x
RVMD Revolution Medicines, Inc.	41.6B	2.47x	–	15.97x	−20.3x	−32.0x	−21.0x	−29.8x
ASND Ascendis Pharma A/S	16.6B	2.94x	−31.7%	10.30x	15.2x	24.0x	35.6x	19.5x
BLTE Belite Bio, Inc	6.1B	–	–	7.89x	−51.8x	314.4x	−113.6x	191.9x
CRSP CRISPR Therapeutics AG	4.8B	3.07x	−16,569.8%	2.94x	−11.3x	−14.3x	−6.5x	−7.5x
DNTH Dianthus Therapeutics, Inc.	4.6B	–	−7,973.3%	3.87x	−21.7x	−17.7x	−15.7x	−12.3x
Mean		2.83x	−6,172.1%	7.79x	−15.3x	45.3x	−20.8x	26.3x
Median		2.94x	−4,043.5%	6.82x	−15.8x	−8.4x	−11.1x	−5.7x

Technical analysis

1M+2.7%
3M−23.4%
1Y−36.4%
3Y−50.2%

Financial statements in millions of USD

Income statement in millions of USD, fiscal years

Income statement, REGENXBIO Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Total revenue	170	83.3	90.2	113	470	155
Cost of revenue	20.3	33.6	37.2	54.5	51.8	35.7
Gross profit	150	49.8	53.0	58.2	419	119
Selling, general & administrative expenses	82.9	71.6	88.5	85.3	79.3	63.8
Research & development	228	209	232	242	181	166
Interest expense (income), operating	0.1	0.9	–	–	–	–
Unusual expense (income)	–	2.1	–	–	–	–
Other operating expenses	0.1	0	0.4	−6.7	−2.2	8.0
Operating income	−161	−233	−268	−263	160	−119
Net interest income (expense)	−32.7	6.2	4.5	−17.5	−18.7	13.2
Gain (loss) on sale of assets	–	–	–	–	–	–
Other non-operating income (expense)	0	0	0	0	0	0
Net income before taxes	−194	−227	−264	−280	141	−106
Provision for taxes	0	–	−0.2	−0.1	13.4	5.2
Minority interest	–	–	–	–	–	–
Equity in affiliates	–	–	–	–	–	–
U.S. GAAP adjustment	–	–	–	–	–	–
Net income before extraordinary items	−194	−227	−263	−280	128	−111
Extraordinary items	–	–	–	–	–	–
Net income	−194	−227	−263	−280	128	−111
EBIT, normalized	−161	−230	−268	−263	160	−119
EBITDA, normalized	−145	−214	−251	−250	170	−111
Basic EPS, normalized	−3.76	−4.59	−6.02	−6.50	2.91	–

Balance sheet in millions of USD, fiscal years

Balance sheet, REGENXBIO Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Assets
Cash & short-term investments	230	235	275	365	457	476
Receivables	38.3	20.5	24.8	28.1	32.4	43.0
Total inventory	–	–	–	–	–	–
Prepaid expenses	11.9	9.1	14.5	13.9	18.8	10.5
Other current assets	1.0	13.8	20.4	9.4	10.2	2.0
Total current assets	281	278	335	416	519	531
Property, plant & equipment	152	171	193	207	192	120
Goodwill	–	–	–	–	–	–
Intangibles	–	–	–	–	–	–
Long-term investments	10.8	10.2	38.9	201	392	46.8
Note receivable	2.3	0.5	0.7	1.5	2.3	3.3
Other long-term assets	6.6	6.0	6.8	8.4	8.5	6.6
Total assets	453	466	574	833	1,114	708
Liabilities
Accounts payable	21.4	22.8	22.8	27.2	11.4	10.6
Payable/accrued	–	–	–	–	–	–
Accrued expenses	46.7	46.0	56.8	52.8	66.5	48.4
Short-term debt	0	0	0	0	0	0
Current portion of long-term debt	39.6	34.3	50.6	48.6	37.9	18.8
Other current liabilities	10.5	0.1	0.1	1.8	14.7	3.6
Total current liabilities	118	103	130	130	130	81.4
Long-term debt	147	25.4	43.5	89.0	133	175
Minority interest	–	–	–	–	–	–
Other liabilities	84.8	77.8	88.5	97.6	85.7	74.5
Total liabilities	350	206	262	317	350	330
Shareholders' equity
Preferred stock	–	–	–	–	–	–
Common stock	0	0	0	0	0	0
Additional paid-in capital	1,229	1,193	1,021	973	928	667
Retained earnings (accumulated deficit)	−1,126	−932	−705	−442	−161	−289
Treasury stock	–	–	–	–	–	–
Other equity	−0.7	−0.7	−4.4	−15.4	−2.6	−0.4
Total equity	103	260	312	516	764	378
Total liabilities & shareholders' equity	453	466	574	833	1,114	708

Cash flow statement in millions of USD, fiscal years

Cash flow statement, REGENXBIO Inc., fiscal years, most recent first
	2025	2024	2023	2022	2021	2020
Operating activities
Net income	−194	−227	−263	−280	128	−111
Depreciation, depletion & amortization	15.6	16.2	17.3	12.9	9.6	8.4
Deferred taxes	–	–	–	–	–	–
Non-cash items	42.5	32.2	38.7	45.9	41.3	34.6
Changes in working capital	11.8	5.5	−10.9	14.0	40.2	14.2
Cash from operations	−124	−173	−218	−207	219	−54.1
Investing activities
Capital expenditures	−2.4	−2.4	−10.0	−30.7	−84.2	−26.9
Other investing cash flows	−13.5	106	201	18.8	−322	150
Cash from investing	−15.9	103	191	−11.9	−407	123
Financing activities
Financing cash flow items	144	−0.3	−0.5	0	−0.6	193
Cash dividends paid	–	–	–	–	–	–
Issuance (retirement) of debt, net	–	–	–	–	–	–
Other financing cash flows	−27.4	93.0	−34.5	−28.8	196	7.4
Cash from financing	117	92.7	−35.0	−28.8	195	200
Foreign exchange effects	–	–	–	–	–	–
Net change in cash	−23.1	23.0	−62.4	−248	7.5	269
Free cash flow	−126	−176	−228	−238	135	−80.9

Disclaimer

The financial data presented in this report is delayed and obtained from sources QDD Research believes to be reliable, including stock exchanges, SEDAR, and EDGAR. However, no representation or warranty is made as to the accuracy, completeness, or timeliness of the information. QDD Research accepts no liability for any errors, omissions, or financial losses arising from the use of this data.

This report is generated using a fully systematic and quantitative approach. All factor scores and the overall quant rating (ranging from D to A+) are derived from algorithmic models and are based solely on objective financial metrics. These scores are intended for informational purposes only and should not be interpreted as investment advice or a recommendation to buy, sell, or hold any securities.

QDD Research is not a registered investment advisor or broker-dealer and does not provide personalized financial advice. The content is not tailored to the specific investment goals, financial situation, or risk profile of any individual investor. We strongly encourage readers to consult with a licensed broker or investment advisor before making any investment decisions based on the information contained in this report.

Live quote provided by TradingView. Report data updated Nov 3, 2026 after market close.